Dienogest in long-term treatment of endometriosis
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Endometriosis is a chronic disease primarily affecting women of childbearing age, in which endometriotic lesions form outside the uterus, typically leading to painful symptoms, fatigue, and infertility. The symptoms of endometriosis may cause significant impairment in quality of life and represent a substantial economic burden to patients, families, and society. There is no cure for endometriosis; management consists of alleviating pain and other symptoms, reducing endometriotic lesions, and improving quality of life. Recurrence after surgical intervention is common, while the clinical evidence to support the efficacy and safety of many medications currently used in endometriosis is limited. Dienogest is an oral progestin that has been investigated extensively in the treatment of endometriosis in two clinical programs performed in Europe and Japan, including dose-ranging, placebo-controlled, active comparator-controlled, and long-term (up to 65 weeks) studies. These studies demonstrated that dienogest 2 mg daily effectively alleviates the painful symptoms of endometriosis, reduces endometriotic lesions, and improves indices of quality of life. Dienogest showed a favorable safety and tolerability profile in these studies, with predictable adverse effects, high rates of patient compliance, and low withdrawal rates. This review article describes the clinical trial evidence that characterizes the efficacy and safety of dienogest in endometriosis, including two studies characterizing dienogest in long-term use. The relevance of these findings to the management of endometriosis in clinical practice is discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Revised American Society for Reproductive Medicine classification of endometriosis: 1996
American Society for Reproductive Medicine (1997) · Fertility and Sterility · doi:10.1016/s0015-0282(97)81391-x · Cited by 3,018
ESHRE guideline for the diagnosis and treatment of endometriosis
Kennedy, S., Bergqvist, A., Chapron, C., D’Hooghe, T., Dunselman, G., Greb, R., Hummelshoj, L., Prentice, A., & Saridogan, E. (2005) · Human Reproduction · doi:10.1093/humrep/dei135 · Cited by 1,584 · cited 4×
“4,25 Specific medical therapies that are approved for the treatment of endometriosis include gonadotropin-releasing hormone (GnRH) agonists, danazol, and certain progestins.”
BackgroundInfluentialChronic Pelvic Pain: Prevalence, Health-Related Quality of Life, and Economic Correlates
Mathias, S. (1996) · Obstetrics & Gynecology · doi:10.1016/0029-7844(95)00458-0 · Cited by 1,074
Recurrence of endometriosis and its control
Guo, S.-W. (2009) · Human Reproduction Update · doi:10.1093/humupd/dmp007 · Cited by 719
Strowitzki, T., Marr, J., Gerlinger, C., Faustmann, T., & Seitz, C. (2010) · Human Reproduction · doi:10.1093/humrep/dep469 · Cited by 381 · cited 1×
“57,58 An open-label pilot study of dienogest at the higher dose of 10 mg twice daily for 24 weeks provides additional information on the safety of this medication.”
BackgroundPriorities for Endometriosis Research: Recommendations From an International Consensus Workshop
Rogers, P. A. W., D’Hooghe, T. M., Fazleabas, A., Gargett, C. E., Giudice, L. C., Montgomery, G. W., Rombauts, L., Salamonsen, L. A., & Zondervan, K. T. (2009) · Reproductive Sciences · doi:10.1177/1933719108330568 · Cited by 346
Hormone treatment of endometriosis: The estrogenthreshold hypothesis
Barbieri, R. L. (1992) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(92)91706-g · Cited by 335
Depressive symptoms, anxiety, and quality of life in women with pelvic endometriosis
Sepulcri, R. D. P., & Amaral, V. F. D. (2009) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2008.09.003 · Cited by 304 · cited 1×
“16 The severity of anxiety symptoms correlated with the intensity of pain.”
BackgroundThe impact of endometriosis upon quality of life: a qualitative analysis
Jones, G., Jenkinson, C., & Kennedy, S. (2004) · Journal of Psychosomatic Obstetrics & Gynecology · doi:10.1080/01674820400002279 · Cited by 291
Economic burden of endometriosis
Gao, X., Outley, J., Botteman, M., Spalding, J., Simon, J. A., & Pashos, C. L. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2006.06.015 · Cited by 289
Cited by
Medical Management of Endometriosis
RAFIQUE, S., & DECHERNEY, A. H. (2017) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000292 · Cited by 173
Vercellini, P., Bracco, B., Mosconi, P., Roberto, A., Alberico, D., Dhouha, D., & Somigliana, E. (2016) · Fertility and Sterility · doi:10.1016/j.fertnstert.2015.11.016 · Cited by 127
Zakhari, A., Edwards, D., Ryu, M., Matelski, J. J., Bougie, O., & Murji, A. (2020) · Journal of Minimally Invasive Gynecology · doi:10.1016/j.jmig.2020.05.007 · Cited by 86
Harada, T., Kosaka, S., Elliesen, J., Yasuda, M., Ito, M., & Momoeda, M. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2017.07.1165 · Cited by 84
Römer, T. (2018) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-018-4864-8 · Cited by 82
Metadata
- Authors
- Schindler, A.
- Venue
- International Journal of Women's Health
- Publisher
- Informa UK Limited
- Published
- 2011-07
- Volume
- 3
- Pages
- 175
- ISSN
- 1179-1411 (ISSN-L)
- OpenAlex
- W2061289968
- Cited by
- 158
- References
- 33
- FWCI
- 5.14
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dienogest in long-term treatment of endometriosis. https://app.cochat.ai/papers/10.2147/ijwh.s5633
- The paper
- Schindler, A. (2011). Dienogest in long-term treatment of endometriosis. International Journal of Women's Health. https://doi.org/10.2147/ijwh.s5633
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.